Phase
Condition
Kidney Cancer
Renal Cell Carcinoma
Renal Cell Cancer
Treatment
an AI-based real-time image-guided kidney model system
Clinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Ages 18-80 years, regardless of gender
Written informed consent obtained from the patient or legally authorizedrepresentative after full protocol disclosure
Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renaltumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score ≤10)
Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023)
Elective minimally invasive partial nephrectomy (laparoscopic/robotic) aftercomprehensive surgical counseling
Exclusion
Exclusion Criteria:
Multifocal renal tumors (bilateral or unilateral)
Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy)within 6 months
Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy)
Intraoperative conversion to radical nephrectomy or open approach
Postoperative adjuvant therapy during protocol-defined follow-up (12 months)
Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR <30 mL/min/1.73m²)affecting outcome assessment
Concurrent enrollment in interventional clinical trials
Investigator-determined ineligibility based on risk-benefit analysis
Study Design
Study Description
Connect with a study center
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
Nanjing, Jiangsu 210036
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.